Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors

Cellular and Molecular Neurobiology

Volumn 26, Issue 4-6, 2006, Pages 407-423

  Dickason Chesterfield, Amy K ^a   Kidd, Stephanie R ^a   Moore, Steven A ^a   Schaus, John M ^a   Liu, Bin ^a   Nomikos, George G ^a   Felder, Christian C ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Anandamide; Cannabinoid; Endocannabinoid; Fatty acid amide hydrolase; LY2183240; Marijuana; Transporter

Indexed keywords

AMIDASE; AMIDE; ANANDAMIDE; ARACHIDONIC ACID DERIVATIVE; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY-ACID AMIDE HYDROLASE;

ANIMAL; ARTICLE; BINDING COMPETITION; BIOLOGICAL MODEL; CELL CULTURE; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME SPECIFICITY; EVALUATION; HELA CELL; HUMAN; METABOLISM; RADIOASSAY; RAT; STRUCTURE ACTIVITY RELATION; TRANSPORT AT THE CELLULAR LEVEL;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT; CELLS, CULTURED; ENDOCANNABINOIDS; HELA CELLS; HUMANS; MODELS, BIOLOGICAL; POLYUNSATURATED ALKAMIDES; RADIOLIGAND ASSAY; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 33745696478     PISSN: 02724340     EISSN: 15736830     Source Type: Journal    
DOI: 10.1007/s10571-006-9072-6     Document Type: Article

References (50)

1. Aquila, B. A., Hopkins, S., Lockshin, C. A., and Wang, F. (2003). Sepracor. Amines that inhibit a mammalian anandamide transporter, and methods of use thereof. WO03097573.
2. Baker, D., Pryce, G., Davies, W. L., and Hiley, C. R. (2006). In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol. Sci. 27(1):1-4. (Pubitemid 43063115)
3. Begg, M., Pacher, P., Batkai, S., Osei-Hyiaman, D., Offertaler, L., Mo, F. M., Liu, J., and Kunos, G. (2005). Evidence for novel cannabinoid receptors. Pharmacol. Ther. 106(2):133-145. (Pubitemid 40613055)
4. Beltramo, M., Stella, N., Calignano, A., Lin, S. Y., Makriyannis, A., and Piomelli, D. (1997). Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277(5329):1094-1097. (Pubitemid 27371630)
5. Boyd, S. T., and Fremming, B. A. (2005). Rimonabant-a selective CB1 antagonist. Ann. Pharmacother. 39(4):684-690.
6. Bracey, M. H., Hanson, M. A., Masuda, K. R., Stevens, R. C., and Cravatt, B. F. (2002). Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 298(5599):1793-1796. (Pubitemid 35404124)
7. Crawley, J. N., Corwin, R. L., Robinson, J. K., Felder, C. C., Devane, W. A., and Axelrod, J. (1993). Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol. Biochem. Behav. 46(4):967-972.
8. Day, T. A., Rakhshan, F., Deutsch, D. G., and Barker, E. L. (2001). Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol. Pharmacol. 59(6):1369-1375. (Pubitemid 32510100)
9. De Petrocellis, L., Bisogno, T., Davis, J. B., Pertwee, R. G., and Di Marzo, V. (2000). Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: Inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS. Lett. 483(1):52-56.
10. Demuth, D. G., and Molleman, A. (2006). Cannabinoid signalling. Life Sci. 78(6):549-563. (Pubitemid 41785760)
11. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., and Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258(5090):1946-1949. (Pubitemid 23026736)
12. Di Marzo, V., Bifulco, M., and De Petrocellis, L. (2004). The endocannabinoid system and its therapeutic exploitation. Nat Rev. Drug Discov. 3(9):771-784. (Pubitemid 39242829)
13. Di Marzo, V., De Petrocellis, L., Sepe, N., and Buono, A. (1996a). Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem. J. 316(Pt 3):977-984.
14. Di Marzo, V., De Petrocellis, L., Sugiura, T., and Waku, K. (1996b). Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-arachidonoyl-glycerol, in mouse neuroblastoma cells. Biochem. Biophys. Res. Commun. 227(1):281-288. (Pubitemid 26370588)
15. Diaz-Laviada, I., and Ruiz-Llorente, L. (2005). Signal transduction activated by cannabinoid receptors. Mini-Rev. Med. Chem. 5(7):619-630. (Pubitemid 40933033)
16. Fegley, D., Kathuria, S., Mercier, R., Li, C., Goutopoulos, A., Makriyannis, A., and Piomelli, D. (2004). Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc. Natl. Acad. Sci. USA 101(23):8756-8761. (Pubitemid 38745844)
17. Fernandez, J. R., and Allison, D. B. (2004). Rimonabant Sanofi-Synthelabo. Curr. Opin. Invest. Drugs 5(4):430-435.
18. Fowler, C. J., Holt, S., Nilsson, O., Jonsson, K. O., Tiger, G., and Jacobsson, S. O. (2005). The endocannabinoid signaling system: pharmacological and therapeutic aspects. Pharmacol. Biochem. Behav. 81(2):248-262. (Pubitemid 40812405)
19. Fowler, C. J., Tiger, G., Ligresti, A., Lopez-Rodriguez, M. L., and Di Marzo, V. (2004). Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis-a difficult issue to handle. Eur. J. Pharmacol. 492(1):1-11. (Pubitemid 38624415)
20. Giang, D. K., and Cravatt, B. F. (1997). Molecular characterization of human and mouse fatty acid amide hydrolases. Proc. Natl. Acad. Sci. USA 94(6):2238-2242. (Pubitemid 27136858)
21. Glaser, S. T., Kaczocha, M., and Deutsch, D. G. (2005). Anandamide transport: a critical review. Life Sci. 77(14):1584-1604. (Pubitemid 41073654)
22. Hillard, C. J., and Jarrahian, A. (2005). Accumulation of anandamide: Evidence for cellular diversity. Neuropharmacology 48(8 SPEC. ISS.): 1072-1078.
23. Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., Mechoulam, R., and Pertwee, R. G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54(2):161-202. (Pubitemid 34575709)
24. Howlett, A. C., Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., and Porrino, L. J. (2004). Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47(Suppl 1):345-358. (Pubitemid 39298276)
25. Iversen, L. (2000). The Science of Marijuana, Oxford University Press, New York, NY.
26. Iversen, L. (2004). How cannabis works in the brain. In Castle, D. and Murray, R. (eds.), Marijuana and Madness: Psychiatry and Neurobiology, Cambridge University Press, New York, NY, pp. 19-40.
27. Jarai, Z., Wagner, J. A., Varga, K., Lake, K. D., Compton, D. R., Martin, B. R., Zimmer, A. M., Bonner, T. I., Buckley, N. E., Mezey, E., Razdan, R. K., Zimmer, A., and Kunos, G. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. USA 96(24):14136-14141.
28. Jarrahian, A., Manna, S., Edgemond, W. S., Campbell, W. B., and Hillard, C. J. (2000). Structure-activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter. J. Neurochem. 74(6):2597-2606. (Pubitemid 30314238)
29. Kaczocha, M., Hermann, A., Glaser, S. T., Bojesen, I. N., and Deutsch, D. G. (2006). Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by FAAH. J. Biol. Chem.: M509721200.
30. Kathuria, S., Gaetani, S., Fegley, D., Valino, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., La Rana, G., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V., and Piomelli, D. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9(1):76-81. (Pubitemid 36098263)
31. Kenakin, T. P. (1997). Pharmacologic Analysis of Drug-Receptor Interaction. Lippincott-Raven, New York, NY.
32. Kreuz, D. S., and Axelrod, J. (1973). Delta-9-tetrahydrocannabinol: localization in body fat. Science 179(71):391-393.
33. Lambert, D. M., and Fowler, C. J. (2005). The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J. Med. Chem. 48(16):5059-5087. (Pubitemid 41113892)
34. Lopez-Rodriguez, M. L., Viso, A., Ortega-Gutierrez, S., Fowler, C. J., Tiger, G., de Lago, E., Fernandez-Ruiz, J., and Ramos, J. A. (2003). Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. J. Med. Chem. 46(8):1512-1522. (Pubitemid 36512714)
35. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., and Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346(6284):561-564.
36. McFarland, M. J., and Barker, E. L. (2004). Anandamide transport. Pharmacol. Ther. 104(2):117-135. (Pubitemid 39424256)
37. Moore, S. A., Nomikos, G. G., Dickason-Chesterfield, A. K., Schober, D. A., Schaus, J. M., Ying, B. P., Xu, Y. C., Phebus, L., Simmons, R. M., Li, D., Iyengar, S., and Felder, C. C. (2005). Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc. Natl. Acad. Sci. USA 102(49):17852-17857. (Pubitemid 41803586)
38. Munro, S., Thomas, K. L., and Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365(6441):61-65. (Pubitemid 23305569)
39. Ortar, G., Ligresti, A., De Petrocellis, L., Morera, E., and Di Marzo, V. (2003). Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem. Pharmacol. 65(9):1473-1481. (Pubitemid 36559598)
40. Patricelli, M. P., and Cravatt, B. F. (2001). Characterization and manipulation of the acyl chain selectivity of fatty acid amide hydrolase. Biochemistry 40(20):6107-6115. (Pubitemid 32466315)
41. Patricelli, M. P., Lashuel, H. A., Giang, D. K., Kelly, J. W., and Cravatt, B. F. (1998). Comparative characterization of a wild type and transmembrane domain-deleted fatty acid amide hydrolase: identification of the transmembrane domain as a site for oligomerization. Biochemistry 37(43):15177-15187. (Pubitemid 28503247)
42. Patricelli, M. P., Lovato, M. A., and Cravatt, B. F. (1999). Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolases with distinct catalytic properties. Biochemistry 38(31):9804-9812.
43. Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., and Group, R. I.-N. A. S. (2006). Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295(7):761-775. (Pubitemid 43244304)
44. Piomelli, D., Beltramo, M., Giuffrida, A., and Stella, N. (1998). Endogenous cannabinoid signaling. Neurobiol. Dis. 5(6 Pt B):462-473. (Pubitemid 29075845)
45. Ravinet Trillou, C., Arnone, M., Delgorge, C., Gonalons, N., Keane, P., Maffrand, J. P., and Soubrie, P. (2003). Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284(2):R345-R353. (Pubitemid 36120150)
46. Rinaldi-Carmona, M., Barth, F., Heaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D., et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350(2-3):240-244. (Pubitemid 24268029)
47. Shire, D., Carillon, C., Kaghad, M., Calandra, B., Rinaldi-Carmona, M., Le Fur, G., Caput, D., and Ferrara, P. (1995). An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem. 270(8):3726-3731.
48. Sun, Y. X., Tsuboi, K., Okamoto, Y., Tonai, T., Murakami, M., Kudo, I., and Ueda, N. (2004). Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem. J. 380(Pt 3):749-756. (Pubitemid 38850516)
49. Vandevoorde, S., and Fowler, C. J. (2005). Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate. Br. J. Pharmacol. 145(7):885-893. (Pubitemid 41129010)
50. Wilson, S. J., Lovenberg, T. W., and Barbier, A. J. (2003). A high-throughput-compatible assay for determining the activity of fatty acid amide hydrolase. Anal. Biochem. 318(2):270-275. (Pubitemid 36694119)